2020

主页/标签: 2020

Oramed’s Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients

91% of T1D patients and 85% of T2D patients surveyed indicated they were "extremely likely" or "very likely" to ask their doctors about ORMD-0801 NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on [...]

2020-09-15T08:25:00+00:00分类:新闻通稿|标签:|

Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin

Data Presented at the American Diabetes Association Scientific Session 2020 NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its [...]

2020-06-15T08:25:00+00:00分类:新闻通稿|标签:|

Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June

Three Poster Presentations Granted to Discuss Oral Insulin Candidate ORMD-0801 NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th [...]

2020-05-05T07:55:00+00:00分类:新闻通稿|标签:|

Oramed Patent in Canada Allowed for Oral Delivery of Proteins

NEW YORK, April 7, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Patent Office has indicated its intent to grant the Company a patent [...]

2020-04-07T07:40:00+00:00分类:新闻通稿|标签:|

Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million

NEW YORK, Feb. 27, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or "Company"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the pricing of an underwritten public offering of 5,250,000 shares of its common stock [...]

2020-02-27T09:15:00+00:00分类:新闻通稿|标签:|